Enterprise Value
4.161B
Cash
305.7M
Avg Qtr Burn
-20.14M
Short % of Float
8.12%
Insider Ownership
4.65%
Institutional Own.
99.47%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Acazicolcept (ALPN-101) Details Systemic lupus erythematosus | Phase 2 Data readout | |
Povetacicept (ALPN-303) Details Autoimmune disease, Autoimmune nephritis, Immune complex membranoproliferative glomerulonephritis, IgA nephropathy | Phase 2 Data readout | |
Povetacicept (ALPN-303) Details Autoimmune disease, Systemic lupus erythematosus | Phase 2 Initiation | |
Povetacicept (ALPN-303) Details Autoimmune disease, Primary immune thrombocytopenia | Phase 1b Update | |
Davoceticept (ALPN-202) (CD28 costimulator) Details Advanced malignancies | Failed Discontinued |